[Seminar iNOVA4Health] Challenges of the pharmaceutical industry and its implications for collaborators

Title: Challenges of the pharmaceutical industry and its implications for collaborators

Speaker: Harald Dinter

Affiliation: Independent Consultant (Formerly BAYER AG).

Short CV:

Dr. Harald Dinter is an Independent Consultant to Biotech and Pharmaceutical Companies in the areas of business strategy, acquisitions and technology licensing. Prior to his role as independent consultant Dr. Harald Dinter was Senior Vice President and Head of Biologics at Bayer Pharma AG where he led the company through multiple processes of clinical testing and compliance.

Dr. Harald Dinter has a PhD in Biotechnology from the German Institute for Biotechnological Research and several research articles published in distinguished journals. Dr. Harald Dinter has contributed for the development of different therapeutic molecules, such as small molecules, monoclonal antibodies and antibody fragments since the early 90s. With a focus in clinical development and manufacturing Dr. Harald has a long track record in the field of Drug Discovery and Drug Development. He was in the front line of immunotherapy for diseases such as cancer and blood disorders.

In the seminar “Challenges of the pharmaceutical industry and its implications for collaborators” Dr. Harald Dinter will share his perspective over academic-industry partnerships and how can scientists from both ends get the best part of the deal.

Selected Publications:

1. Zhao, XY, et al. Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors (2016) Clinical Cancer Drugs 3: 76-86.
2. Mathew, P, et al. Inhibitors in Haemophilia A: A Perspective on Clotting Factor Products as a Potential Contributing Factor (2016) Haemophilia 22: 334-41.
3. Fawaz, FS, et al. Allogenic somatic cell therapy: process development challenges and future opportunities. (2011) Curr. Opin. Mol. Ther. 12: 383-5.
4. Feldman, RI, et al. Potent triazolothione inhibitor of heat-shock protein-90. (2009) Chem. Biol. Drug Des. 74: 43-50.
5. Zhao, XY, et al. Tomoregulin internalization confers selective toxicity on prostate cancer cells. (2008) Translational Oncology 1: 102-109.